Navigation Links
DOR BioPharma Reports 2nd Quarter and 1st Half 2009 Financial Results and Reviews Recent Accomplishments
Date:8/14/2009

lts in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including DOR201, orBec(R) and LPM(TM), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others m
'/>"/>
SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
3. Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University
4. DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD
5. PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5, 2009
6. Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology
7. Big Pharma to Big Biopharma: Frost & Sullivan Examines the Latest M&A Trends and Opportunities
8. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
9. DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
10. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
11. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... LEXINGTON, Mass. , Sept. 22, 2014 /PRNewswire/ ... GEVA ), a biopharmaceutical company developing ... appointment of Robert Bazemore as Chief ... Patel , President and Chief Executive Officer, Robert ... the company,s lead program, sebelipase alfa for LAL ...
(Date:9/21/2014)... of Basel in Switzerland have succeeded in observing ... for the first time. These extremely weak spectra ... properties and may also contribute to the development ... were published in the scientific journal Nature ... interaction between matter and light, is probably the ...
(Date:9/21/2014)... Chemical Sciences play a significant ... clean air and safe water, healthy food, and ... environmentalists, food scientists, educators, and scientists have a ... field of Chemistry for the national development, and ... of the fastest emerging Sciences, accelerating with a ...
(Date:9/20/2014)... September 20, 2014 HealthTronics, ... and interventional radiology products and services, has signed ... with Clinicon Corporation for its high ... portfolio of minimally invasive, mobile, surgical technology—offering more ... Under the agreement, HealthTronics will make available Clinicon’s ...
Breaking Biology Technology:Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 2Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 3Synageva BioPharma Appoints Robert Bazemore As Chief Operating Officer 4Uncovering the forbidden side of molecules 2Chemistry for Global Development during the Open Access Week 2Chemistry for Global Development during the Open Access Week 3HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3
... Consolidated service revenue of $238.7 million grows 32% year-over-year, - ... - Backlog increases ... - Net quarterly book-to-burn ratio ... PRXL ) today announced its financial results for the,second quarter ...
... of Family Cord Blood Banks, LOS ANGELES, ... of California Cryobank, today announced that its co-founder ... appointed to the Department,of Health and Human Services, ... on Blood Stem Cell Transplantation,(ACBSCT). Through his appointment, ...
... required milestone for functional food partners and ... /PRNewswire-FirstCall/ - Neptune Technologies &,Bioressources Inc. ("Neptune") ... Oil ("NKO(R)") has been determined to be,safe ... status required for the,commercialization of NKO(R) incorporated ...
Cached Biology Technology:PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 2PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 3PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 4PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 5PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 6PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 7PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 8PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 9PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 10Dr. Charles A. Sims of California Cryobank's Family Cord Blood Services Named to National Stem Cell Advisory Council 2Dr. Charles A. Sims of California Cryobank's Family Cord Blood Services Named to National Stem Cell Advisory Council 3Neptune Technologies receives GRAS notification in the United States 2Neptune Technologies receives GRAS notification in the United States 3
(Date:9/21/2014)... team of Stanford researchers has developed a protein therapy ... break away from original tumor sites, travel through the ... the body. , This process, known as metastasis, can ... "The majority of patients who succumb to cancer fall ... Cochran, an associate professor of bioengineering who describes a ...
(Date:9/19/2014)... study multifunctional and specialized spinal cord nerve cells ... Foundation grant in the amount of $680,000 for ... the Department of Biology, OU College of Arts ... the multifunctional and specialized spinal cord nerve cells ... connections they make. Berkowitz will collaborate with ...
(Date:9/19/2014)... A new study shows that legume plants regulate ... cytokininssignaling molecules that are transmitted through the plant ... the number of bacteria-holding nodules in the roots. ... the National Institute for Basic Biology, the Graduate ... Center for Sustainable Resource Science in Japan. ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4For legume plants, a new route from shoot to root 2
... motor excitability have a better working memory than humans with ... by scientists from the Transfacultary Research Platform at the University ... drawn as to the general cortical excitability as well ... temporary storage of information such as memorizing a phone number ...
... found new clues to how plants evolved to withstand wintry ... issue of the journal Nature , the team constructed ... plants the largest time-scaled evolutionary tree to date. By ... stem data for thousands of species, the researchers were able ...
... The Scripps Research Institute (TSRI) have demonstrated a drug-discovery ... of chemical compounds that have a desired effect on ... To illustrate the power of the innovative technique, the ... shows promise for treating obesity-linked diabetes. At the same ...
Cached Biology News:Motor excitability predicts working memory 2Study offers clues to how plants evolved to cope with cold 2Study offers clues to how plants evolved to cope with cold 3Innovative screening strategy swiftly uncovers new drug candidates, new biology 2Innovative screening strategy swiftly uncovers new drug candidates, new biology 3Innovative screening strategy swiftly uncovers new drug candidates, new biology 4
... Drosophila S2 cells are used for heterologous ... System (DES). The S2 cell line was ... (20-24 hours old) Drosophila melanogaster embryos ... at room temperature without CO2 and is easily ...
Mouse monoclonal antibody to RAD51L3 - RAD51-like 3 (S. cerevisiae)...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. Feature: tissue-culture treated yes ... cm 2 D H 60 ...
... Nop1p/Fibrillarin was originally identified ... yeast, Saccharomyces cerevisiae (accession P15646). The ... viability and is localized in the ... is fibrillarin (accession P22087) a component ...
Biology Products: